The present disclosure provides phospholipid-containing compounds, pharmaceutical compositions and microspheres that exhibit high affinity for mineralized metals. The present disclosure also provides strategies for using said compounds, compositions and microspheres in the treatment of nephrolithiasis or kidney stone disease, and methods of manufacturing and preparing said compounds and compositions.

A method for encapsulating a compound of interest in a matrix may include preparing a first aqueous solution including the compound of interest and a gelating agent. An oil or oil mixture and a second aqueous solution having a gelation inducing agent are prepared. The first aqueous solution is emulsified in the oil or oil mixture to form an emulsion of aqueous solution droplets in oil. That emulsion is emulsified in the second aqueous solution. The gelation inducing agent from the second aqueous solution is diffused through the oil towards the interface of the oil and the first aqueous solution. Gelation of the gelating agent at the interface forms the matrix, wherein particles are obtained including the matrix composed of the gelified gelating agent and encapsulating the compound of interest.

The present invention relates in part to novel cationic lipids and their use, e.g., in delivering nucleic acids to cells.

Provided herein are controlled release multiparticulate dosage forms containing deutetrabenazine for use in the treatment of, e.g., hyperkinetic movement disorders. When orally administered to a subject on a once-daily basis, the dosage forms provide a favorable pharmacokinetic profile.

Methods for treating cutaneous conditions and dermatoses such as disorders of the skin, subcutaneous tissues, mucous membranes, poorly vascularized tissues and/or other tissue disorders, including erosions, fissures, transient and/or chronic sores, burns, wounds, ulcers, lesions and infections. In particular embodiments, treatments include methods for improving skin and related tissue healing and repair using oxygen microbubbles (OMBs) and/or various formulations and/or compounds incorporating OMBs in combination with various other medicaments and/or tissue implants.

A polymer nanoparticle includes a crosslinked polymer complex including a cargo encapsulated in a crosslinked polymer network; and a coating on the crosslinked polymer complex. The coating is derived from a cellular membrane. The polymer nanoparticles described herein can advantageously be used to deliver a cargo molecule (e.g., a nucleic acid) to a target location, for example upon administration to a subject in need of therapy.

A nanotherapeutic supported by a hierarchical silica composite with dual imaging capability (e.g. fluorescence and magnetic resonance imaging), a method of preparing the nanotherapeutic, and a method of treating cancer. Also disclosed is a method of oxidatively dehydrogenating ethane using a catalytic system supported by a hierarchical silica composite.

The present invention relates to a particulate nano-lipid carrier for the encapsulation of a bioactive material, and a method for producing same, and more specifically, to a particulate nano-lipid carrier having excellent nanoparticle stability and improved encapsulation of water-soluble drugs. A nano-lipid carrier according to the present invention has significantly improved bioactive material stability and encapsulation efficiency compared to conventional carriers, and it is anticipated that the nano-lipid carrier according to the present invention will be immediately commercializable as a raw material for cosmetics by means of a hair follicle targeting production method suitable for mass production.

Modified release formulations of gamma-hydroxybutyrate having improved dissolution and pharmacokinetic properties are provided, and therapeutic uses thereof.

Modified release formulations of gamma-hydroxybutyrate having improved dissolution and pharmacokinetic properties are provided, and therapeutic uses thereof.